Romiplostim Reduces Platelet Transfusion Needs in Multiple Myeloma Patients Undergoing Autologous Stem Cell...

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Melphalan-induced thrombocytopenia lacks standard accelerated recovery treatments in multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT).
• Romiplostim, a thrombopoietin receptor agonist, is designed to enhance platelet production.

Purpose of the Study:

• To evaluate the efficacy and safety of romiplostim in minimizing platelet transfusions post-ASCT for MM patients.
• To assess the impact of romiplostim on platelet engraftment timelines and transfusion requirements.

Main Methods:

• An investigator-initiated, single-center, open-label pilot study compared 18 MM patients receiving pegylated GCSF and romiplostim post-ASCT with 56 historical controls receiving GCSF alone.
• Efficacy endpoints included mean single donor platelet (SDP) and packed red blood cell (PRBC) transfusions, and time to platelet and neutrophil engraftment.

Main Results:

• The romiplostim cohort required significantly fewer SDP transfusions (1.39 vs. 3.40, p=0.0001) and experienced faster platelet engraftment (9.72 vs. 12.57 days, p=0.0018) compared to controls.
• Neutrophil engraftment and PRBC transfusion needs were similar between groups.
• No deaths or significant safety issues were observed.

Conclusions:

• Romiplostim demonstrated superior efficacy in reducing platelet transfusions and accelerating platelet recovery post-ASCT in MM patients.
• The drug exhibited a favorable safety profile, suggesting its potential as a therapeutic option for managing thrombocytopenia after ASCT.